Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP-IT RCT
2023-506194-35-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of floxuridine, fluorouracil, oxaliplatin, irinotecan, capecitabine and 2 more in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Planned start Jul 2024; status: authorised.
02
Drugs
floxuridinefluorouraciloxaliplatinirinotecancapecitabine
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2023-506194-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506194-35-00.